van Nguyen, MD
Cardiovascular Disease · Safety Harbor, FLNPI 1205898236
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,734 of the $17,327 with a category attached, or 79.3%. Amgen accounts for 85.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $10,028 and has fallen 93.0% since, to $701 in 2025.
Across 183 payments — averaging $94.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- Pfizer$453
- AstraZeneca$334
- Alnylam Pharmaceuticals Inc.$235
- Novartis$223
- Amarin Pharma, Inc.$217
- plus $1K from 16 others
Across 409 payments — averaging $1536.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$392K
- Boehringer Ingelheim International GmbH$108K
- Boehringer Ingelheim Pharma GmbH & Co.kg$64K
- Merck$41K
- Alnylam Pharmaceuticals Inc.$23K
What the payments were for
- Speaking & faculty fees$13,73479%
- Food & beverage$3,59321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 48 | $14,783 |
| Pfizer | 30 | $453 |
| AstraZeneca | 14 | $334 |
| Alnylam Pharmaceuticals Inc. | 8 | $235 |
| Novartis | 14 | $223 |
| Amarin Pharma, Inc. | 14 | $217 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $216 |
| E.r. Squibb & Sons, L.L.C. | 15 | $206 |
| Boehringer Ingelheim | 4 | $170 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Johnson & Johnson | 5 | $66 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Novo Nordisk | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Nuwellis, Inc. | 1 | $36 |
| Medtronic | 1 | $32 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Chiesi USA, Inc. | 2 | $25 |
| Boston Scientific | 1 | $19 |
| Biosense Webster, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,327 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 392 | $461,588 |
| XareltoRivaroxaban | 364 | $438,272 |
| EntrestoSacubitril/Valsartan | 96 | $146,654 |
| Repatha SureclickEvolocumab | 102 | $98,968 |
| BrilintaTicagrelor | 48 | $52,618 |
| VascepaIcosapent Ethyl | 43 | $38,400 |
| Ezetimibe | 654 | $17,196 |
| Metoprolol Succinate | 813 | $13,177 |
| FarxigaDapagliflozin Propanediol | 11 | $10,564 |
| Ranolazine ErRanolazine | 44 | $8,210 |
| Praluent PenAlirocumab | 16 | $7,592 |
| ClopidogrelClopidogrel Bisulfate | 605 | $7,266 |
| Amiodarone Hcl | 95 | $7,221 |
| CorlanorIvabradine Hcl | 12 | $7,198 |
| Rosuvastatin Calcium | 532 | $6,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $453 | $461,588392 claims |
| Johnson & JohnsonXarelto | $66 | $438,272364 claims |
| NovartisEntresto | $223 | $146,65496 claims |
| AstraZenecaBrilinta, Farxiga | $334 | $63,18259 claims |
| AmgenCorlanor | $14,783 | $7,19812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Safety Harbor
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.